A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine
A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine
The purpose of this clinical research study is to assess the safety and effectiveness of
 switching to entecavir compared to continued lamivudine in patients with chronic hepatitis B.
-  Male and female subjects =/> 16 years of age (or minimum age required in a given
 country) with history of HBeAg-positive chronic hepatitis B infection;

 -  Incomplete response to current lamivudine therapy;

 -  HBeAg-positive;

 -  Absence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus
 (HCV), or hepatitis D virus (HDV);

 -  Absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease.